Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 11, 2026
Daily News
May 11, 2026
- Arava Safety Backup at Risk as Questran Supply Falters on Nitrosamine Issue
May 11, 2026
- Daiichi Sankyo Cuts FY2025 Profit Outlook on ADC Supply Plan Review
May 11, 2026
- Capricor Sues Nippon Shinyaku over US Rights to DMD Cell Therapy
May 11, 2026
- FDA Delays Review of Leqembi Iqlik for Alzheimer’s Initiation Therapy
May 11, 2026
- Kyorin, Susmed Start Pivotal Trial of Tinnitus Therapy App
May 11, 2026
- Kyorin Begins Japan PIII Trial of Beova in Pediatric OAB
May 11, 2026
- Kyowa Kirin Keeps Long-Term KPIs despite OX40 Setback, Ups 2026 Core Profit Outlook
May 11, 2026
- Onychomycosis Drug Jublia Now Available in Germany: Kaken
May 11, 2026
- Fujifilm Bags Japan Approval for Meniscus Regenerative Therapy
May 11, 2026
- Takeda Logs Positive PII/III Results for TAK-881 in PID, Eyes FY2026 Filing
May 11, 2026
- Kyowa Kirin to Consolidate Domestic Research Sites in Yokohama
May 11, 2026
- Kissei Sublicenses Taiwan Rights for Rigel’s AML Drug to OEP
May 11, 2026
- Japan Review Underway for Rhythm’s Acquired Hypothalamic Obesity Drug
May 11, 2026
- Deciphera Portfolio Powers Ono to Record Sales as It Eyes Post-Opdivo Era
May 11, 2026
- Daiichi Sankyo Healthcare to Raise Prices of OTC Drugs amid Inflation
May 11, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…